Key result
High-dose statins linked to ~70% lower cardiovascular mortality in familial hypercholesterolemia.
Answers are grounded in this paper and cite their sources.
This review article assesses the clinical features, diagnosis and management of familial hypercholesterolemia (FH). FH is mostly an autosomally dominantly inherited with an incidence of 1 in 250. Tendon xanthomata are pathognomonic. Untreated FH is associated with 100-200 fold increase in risk of cardiovascular disease (CVD). FH is diagnosed by screening for elevated low density lipoprotein cholesterol (LDL-C) and confirmed by DNA techniques. Once index cases have been identified cascade family screening should occur. FH is primarily treated with high dose statin therapy. This reduces progression of surrogate markers of coronary arterial disease and registry studies show a 70% long-term decrease in CVD mortality. The justification for other lipidlowering therapies e.g., ezetimibe relies on the high population attributable risk of LDL-C in FH. Novel therapies with greater LDL-C reducing actions such as proprotein convertase subtilisin kexin-9 inhibitors show promise in FH Children with FH should be identified through cascade screening but drug treatment is dependent on LDL-C and family history. They should be managed in specialist paediatric units or in family clinics. Cases of homozygous FH are rare. This orphan condition should be managed in specialist centers with a combination of drug therapy, apheresis and liver transplantation. Novel therapies for the treatment of homozygous FH such as mipomersen and lomitapide are gradually coming into use FH is a common underdiagnosed condition. Current, let alone future, therapies are extremely effective in reducing both LDL-C and CVD events in patients with FH. Identification and treatment of FH should be a feature of preventative CVD medicine programmes.
No takes yet. Share an insight, caveat, or question.
Anthony S. Wierzbicki (2014) conducted a review in Familial hypercholesterolemia (FH). High-dose statin therapy and other lipid-lowering therapies (ezetimibe, PCSK9 inhibitors, mipomersen, lomitapide) was evaluated on Cardiovascular disease (CVD) mortality and LDL-C reduction (70% decrease in CVD mortality (from registry studies)). High-dose statin therapy in familial hypercholesterolemia is associated with a 70% long-term decrease in cardiovascular disease mortality in registry studies, where untreated risk is 100-200 fold higher.
Synapse has enriched 10 related papers. Consider them for comparative context: